{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:53:31Z","timestamp":1793778811585,"version":"4.6.1"},"reference-count":39,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the increased availability and use of novel therapies for multiple myeloma, early mortality is a pervasive challenge with a significant impact on older adults. Reported rates and predictors of early mortality have varied in the literature, with most studies seldom focusing on community\u2010treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort analysis of a real\u2010world electronic health record\u2013derived deidentified database of 7512 patients newly diagnosed with multiple myeloma between January 1, 2011, and February 2, 2021, and treated primarily in US\u2010based community oncology practices, factors associated with early mortality (defined as death within 6 months after the multiple myeloma diagnosis) were examined with the use of binary logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 70\u00a0years overall. We found an overall early mortality rate of 8.3%, with 73% of early deaths occurring in those aged \u226570\u00a0years. Among the early deaths, only 49 patients (8.7%) had documented disease progression before death (median time to progression, 30\u00a0days [interquartile range, 7\u201353 days]). Baseline factors associated with higher odds of early mortality included an Eastern Cooperative Oncology Group performance status (ECOG PS)\u00a0\u2265\u00a02, Revised International Staging System (R\u2010ISS) stage III, an age \u2265 70 years, receipt of proteasome inhibitor\u2013doublet therapy, a light\u2010chain isotype, and the presence of renal dysfunction (estimated glomerular filtration rate &lt; 30\u00a0mL\/min). Among those aged \u226570\u00a0years, ECOG PS\u00a0\u2265\u00a02 and R\u2010ISS stage III remained the strongest predictors of early mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Early mortality disproportionately affects older adults (aged \u226570\u00a0years) with multiple myeloma. Interventions to support this population are needed to reduce disparate survival outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain language summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Factors associated with an increased risk of dying within 6 months (early mortality) of a new diagnosis of multiple myeloma (MM) among 7512 mostly community\u2010treated patients with MM were evaluated.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The early mortality rate was 8.3%; among those deaths, 49 patients (8.7%) had documented evidence of MM progression before death.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The risk of early mortality was greatest for older patients (aged \u226570\u00a0years) and those with a poor performance status, poor kidney function, a higher disease stage, and light\u2010chain MM and those receiving two\u2010drug MM therapies.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>These findings highlight the need for supportive interventions geared toward older adults with MM.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34760","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T14:32:18Z","timestamp":1680100338000},"page":"2023-2034","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A real\u2010world data analysis of predictors of early mortality after a diagnosis of multiple myeloma"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-3046","authenticated-orcid":false,"given":"Shakira J.","family":"Grant","sequence":"first","affiliation":[{"name":"Division of Hematology Department of Medicine The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center\/Nebraska Medicine  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-3214","authenticated-orcid":false,"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Medicine The Ohio State University  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Silberstein","sequence":"additional","affiliation":[{"name":"School of Medicine The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-5032","authenticated-orcid":false,"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Cancer Stat Facts: Myeloma. National Cancer Institute. Accessed November 2021. doi:https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100609.2012.01784.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100812\u20102"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24129"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010020\u201005849\u20104"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518757640"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24796"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1101969"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010016\u20102645\u2010y"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23932"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002305"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(10)70187\u2010X"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201008\u2010303487"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.2086"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.023"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001425"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007247"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475\u20106773.13669"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu020"},{"issue":"3","key":"e_1_2_9_27_1","first-page":"172","article-title":"Risk of early death in multiple myeloma","volume":"10","author":"Kumar S","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010117351"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24389"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.33"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3981.3981"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.075051"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15980"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.0329"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201005\u2010432203"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010631200"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1418856"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201012\u2010615187"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100539\u20100"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:35:47Z","timestamp":1760279747000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/cncr.34760"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34760","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"2022-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}